Freeline to Present at Upcoming Investor Conferences
02 mars 2021 07h00 HE
|
Freeline Therapeutics
LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline Announces Expansion of Executive Leadership
16 févr. 2021 07h00 HE
|
Freeline Therapeutics
Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments Chief Financial Officer Brian M. Silver leaving...
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™
08 févr. 2021 16h01 HE
|
Freeline Therapeutics
Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease ...
Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program
08 févr. 2021 07h00 HE
|
Freeline Therapeutics
Targeting initiation of dose confirmation trial by end of 2021 with data readout by end of 2022 Initiation of Phase 3 pivotal trial targeted by mid-2023, with data readout and BLA filing targeted by...
Freeline to participate at Conferences during January 2021
04 janv. 2021 07h00 HE
|
Freeline Therapeutics
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
14 déc. 2020 07h00 HE
|
Freeline Therapeutics
Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with...
Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference
19 nov. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...